Kogenate treatment of previously untreated patients (PUPs) with hemophilia A: Update of safety, efficacy, and inhibitor development after seven study years.

被引：0
|
作者：
Lusher, J
Arkin, S
Abildgaard, CF
Hurst, D
机构：
[1] MT SINAI SCH MED,NEW YORK,NY
[2] WAYNE STATE UNIV,DETROIT,MI
[3] BAYER CORP,BERKELEY,CA
[4] UNIV CALIF DAVIS,SACRAMENTO,CA 95817
来源：
BLOOD | 1996年 / 88卷 / 10期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：1755 / 1755
页数：1
相关论文
共 50 条
  • [41] Anti-FVIII inhibitor incidence in previously untreated patients (PUPS) with hemophilia exposed to Kogenater (GIPSI - German-Italian PUP study on inhibitor)
    Gringeri, A
    Kreuz, W
    Escuriola-Ettinghausen, C
    Santagostino, E
    Saguer, IM
    Bader, R
    Budde, U
    Mannucci, PM
    THROMBOSIS AND HAEMOSTASIS, 1999, : 474 - 474
  • [42] Tailoring hemostatic therapies to lower inhibitor development in previously untreated patients with severe hemophilia A
    Mannucci, P. M.
    Mancuso, M. E.
    Franchini, M.
    JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2016, 14 (07) : 1330 - 1336
  • [43] Timing of inhibitor development in more than 1000 previously untreated patients with severe hemophilia A
    van den Berg, H. Marijke
    Fischer, Kathelijn
    Carcao, Manuel
    Chambost, Herve
    Kenet, Gili
    Kurnik, Karin
    Konigs, Chris
    Male, Christoph
    Santagostino, Elena
    Ljung, Rolf
    BLOOD, 2019, 134 (03) : 317 - 320
  • [44] Inhibitor development, safety and efficacy of Advate® among previously treated patients with hemophilia A in a postmarketing surveillance in Japan
    Fukutake, Katsuyuki
    Taki, Masashi
    Matsushita, Tadashi
    Nogami, Keiji
    Shima, Midori
    Yoshioka, Akira
    Takamatsu, Junki
    Uchikawa, Haruhiko
    Takagi, Hiroshi
    Arai, Morio
    Engl, Werner
    Shirahata, Akira
    INTERNATIONAL JOURNAL OF HEMATOLOGY, 2019, 109 (03) : 336 - 345
  • [45] Inhibitor development, safety and efficacy of Advate® among previously treated patients with hemophilia A in a postmarketing surveillance in Japan
    Katsuyuki Fukutake
    Masashi Taki
    Tadashi Matsushita
    Keiji Nogami
    Midori Shima
    Akira Yoshioka
    Junki Takamatsu
    Haruhiko Uchikawa
    Hiroshi Takagi
    Morio Arai
    Werner Engl
    Akira Shirahata
    International Journal of Hematology, 2019, 109 : 336 - 345
  • [46] Inhibitor development in relation to treatment duration in severe hemophilia A in previously untreated patients: results from the sippet trial
    Peyvandi, F.
    Mannucci, P. M.
    Garagiola, I
    Anzoletti, M. B.
    El-Beshlawy, A.
    El-Alfy, M.
    Madatha, V. R.
    Eshghi, P.
    Varadarajan, R.
    Hanagavadi, S.
    Karimi, M.
    Manglani, M., V
    Ross, C.
    Young, G.
    Seth, T.
    Apte, S.
    Nayak, D.
    Santagostino, E.
    Mancuso, E.
    Gonzalez, A. C. S.
    Owaidah, Tarek M.
    Rosendaal, F. R.
    JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2015, 13 : 321 - 322
  • [47] DETERMINING INHIBITOR-DEVELOPMENT RISK IN PREVIOUSLY UNTREATED HEMOPHILIA-A PATIENTS TREATED (PUPS) WITH RECOMBINANT FACTOR-VIII (RECOMBINATE(TM))
    LEE, ML
    COURTER, S
    GOMPERTS, E
    THROMBOSIS AND HAEMOSTASIS, 1993, 69 (06) : 856 - 856
  • [48] SAFETY OF MONOCLONAL ANTIBODY-PURIFIED FACTOR-IX IN PREVIOUSLY UNTREATED PATIENTS (PUPS) WITH HEMOPHILIA-B
    SHAPIRO, A
    BERGMAN, GE
    THROMBOSIS AND HAEMOSTASIS, 1995, 73 (06) : 1021 - 1021
  • [49] Recombinant factor IX (rFIX) in the treatment of previously untreated patients (PUPS) with severe or moderately severe hemophilia B
    Shapiro, A
    Abshire, T
    Gill, J
    Kisker, T
    Pasi, J
    Rodriguez, D
    Courter, S
    BLOOD, 1998, 92 (10) : 356A - 356A
  • [50] Safety and immunogenicity of recombinant factor VIII (Recombinate(TM)) in previously untreated patients (PUPs): A 6.5 year update
    Gruppo, R
    Bray, GL
    Schroth, P
    Perry, M
    Gomperts, ED
    THROMBOSIS AND HAEMOSTASIS, 1997, : PD663 - PD663
12345